Business
Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union
Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union\r\n \r\n \r\n\r\n\r\nZomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union\r\n\r\n\r\n\r\n\r\n\r\nExpanded agreement strengthens Zomedica's European presence, broadens product portfolio on the market, and positions the Company to capture growth in the multi-billion-dollar global veterinary diagnostics and therapeutic device markets ANN ARBOR, MI, MI / ACCESS Newswire / October 14, 2025 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), an animal health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that it has entered into an expanded distribution agreement with Grovet b.v., a leading equine health company based in the Netherlands. The amended agreement expands Grovet's existing distribution rights for equine therapeutic devices by adding Zomedica's VETIGEL® hemostatic gel and EquiLoop® therapeutic devices, along with its TRUFORMA® in-clinic diagnostic platform for equine and companion animals.\r\n Expanded Scope of International PartnershipThe revised agreement:\r\n \r\n Reinforces Grovet's role as a key distribution partner for equine therapeutic devices, e.g. PulseVet® shock wave systems, along with the TRUFORMA diagnostic platform, across Europe.\r\n Provides Grovet the ability to support Zomedica's entry into the EU companion animal market on a transitional basis, while Zomedica continues to expand its distribution network outside of the equine segment.\r\n Adds VETIGEL hemostatic gel and EquiLooptPEMF devices to Grovet's portfolio, expanding access to innovative therapeutic solutions for veterinarians.\r\n \r\n Importantly, this agreement enables Zomedica to tap into the equine TRUFORMA market in Europe-building on the strong receptivity seen in the United States where equine veterinarians have rapidly adopted TRUFORMA assays for eACTH and insulin monitoring-while further underscoring the Company's strategy of accelerating global market penetration by aligning with strong regional partners and leveraging their established customer relationships.\r\n Larry Heaton...